XTL Biopharmaceuticals Ltd. (TLV:XTLB)
Israel · Delayed Price · Currency is ILS · Price in ILA 2.000
0.00 (0.00%)
Aug 3, 2026, 5:13 PM IDT
XTL Biopharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.08 | 0.37 | 1.4 | 2.09 | 2.97 |
Trading Asset Securities | - | 0.77 | 0.61 | 1.63 | 3.16 |
Cash & Short-Term Investments | 0.08 | 1.14 | 2.01 | 3.72 | 6.13 |
Cash Growth | -93.35% | -43.02% | -46.09% | -39.27% | 1.41% |
Accounts Receivable | - | 0.1 | - | - | - |
Receivables | - | 0.1 | - | - | - |
Prepaid Expenses | - | 0.05 | 0.03 | 0.07 | 0.09 |
Other Current Assets | 0.09 | 0.05 | 0.01 | 0.01 | 0.02 |
Total Current Assets | 0.17 | 1.34 | 2.05 | 3.81 | 6.24 |
Property, Plant & Equipment | - | 0.19 | - | - | 0 |
Goodwill | - | 3.19 | - | - | - |
Other Intangible Assets | - | 3.82 | 0.38 | 0.38 | 0.38 |
Other Long-Term Assets | - | 0.01 | - | - | - |
Total Assets | 0.17 | 8.55 | 2.43 | 4.19 | 6.62 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.02 | 0.23 | 0 | 0 | 0 |
Accrued Expenses | 0.13 | 0.55 | 0.21 | 0.19 | 0.23 |
Short-Term Debt | - | 0.14 | - | - | - |
Current Unearned Revenue | - | 0.02 | - | - | - |
Other Current Liabilities | 0.27 | 1.28 | - | - | - |
Total Current Liabilities | 0.42 | 2.21 | 0.21 | 0.19 | 0.23 |
Long-Term Deferred Tax Liabilities | - | 0.22 | - | - | - |
Other Long-Term Liabilities | - | 0.69 | - | - | 1.05 |
Total Liabilities | 0.42 | 3.12 | 0.21 | 0.19 | 1.29 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 25.14 | 23.14 | 14.12 | 14.12 | 14.12 |
Additional Paid-In Capital | 140.22 | 141.29 | 146.33 | 146.33 | 146.33 |
Retained Earnings | -165.63 | -159.01 | -158.25 | -156.47 | -155.13 |
Comprehensive Income & Other | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
Shareholders' Equity | -0.25 | 5.44 | 2.22 | 4 | 5.33 |
Total Liabilities & Equity | 0.17 | 8.55 | 2.43 | 4.19 | 6.62 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | 0.14 | - | - | - |
Net Cash (Debt) | 0.08 | 1.01 | 2.01 | 3.72 | 6.13 |
Net Cash Growth | -92.44% | -49.90% | -46.09% | -39.27% | 1.41% |
Net Cash Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
Filing Date Shares Outstanding | 982.99 | 881.39 | 544.91 | 544.91 | 544.91 |
Total Common Shares Outstanding | 946.24 | 881.39 | 544.91 | 544.91 | 544.91 |
Working Capital | -0.25 | -0.87 | 1.84 | 3.62 | 6.01 |
Book Value Per Share | -0.00 | 0.01 | 0.00 | 0.01 | 0.01 |
Tangible Book Value | -0.25 | -1.57 | 1.84 | 3.62 | 4.95 |
Tangible Book Value Per Share | -0.00 | -0.00 | 0.00 | 0.01 | 0.01 |